Document is current
Any future updates will be listed below
-
Authors
Wesevich, Austin https://orcid.org/0000-0001-5202-1231
Goldstein, Daniel A.
Paydary, Koosha
Peer, Cody J.
Figg, William D. https://orcid.org/0000-0003-2428-5613
Ratain, Mark J. https://orcid.org/0000-0002-0938-4392
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32CA009566)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007019)
- License Information
-
More Information
Article History
Received: 9 January 2023
Revised: 5 May 2023
Accepted: 12 July 2023
First Online: 4 August 2023
Competing interests
: AW, KP, CJP and WDF declare no competing interests. DAG declares the following interests: institutional research funding (Merck, Bristol-Myers Squibb, and Jennsen); consulting fees (VIVIO Health); and stock ownership (VIVIO Health and TailorMed). MJR is co-founder, director and treasurer of the Optimal Cancer Care Alliance, is an inventor on pending patent applications for low-dose tocilizumab, and has testified as an expert witness on behalf of multiple generic companies regarding the optimal dosing of anticancer agents.
: Not applicable.
: Not applicable.
